Many Siglecs function as inhibitory receptors on innate and adaptive immune cells and may contribute to the attenuation of immune responses to tumors. Siglec 9 on neutrophils and Siglec 7 on NK cells are prominent examples of inhibitory Siglecs that can potentially dampen anti-tumor immunity. CD169 is a Siglec that may function as an adhesion molecule and a facilitator of the recognition and internalization of sialic acid decorated apoptotic bodies and exosomes derived from tumors. It can potentially contribute to both the attenuation as well as the facilitation of anti-tumor immunity.
| INTRODUCTION
The diversity found within carbohydrates is immense when one considers the number of ways different monosaccharides can be linked together and form branched structures within complex glycans, the attachment of various functional groups to sugar carbon atoms, alterations in stereochemistry, and postsynthetic chemical modifications on available hydroxyl groups. Complementing this diversity is the fact that carbohydrates can be recognized by cells through a variety of receptors that mediate events integral to immune responses, including pathogen recognition, cell adhesion and migration, and the regulation of immune cell signaling. Sialic acid, a monosaccharide that decorates glycans found on vertebrate cells, is of interest to immunologists for a number of reasons, largely related to cell migration and cell signaling.
In this review, we will describe the recognition of sialic acid containing ligands by unique Sialic acid-binding immunoglobulin-type lectins (Siglecs) found on the surfaces of both innate and adaptive immune cells. In this way, sialic acid is involved in discrimination between self and non-self and in the regulation of immune cells. However, pathogens and tumor cells have evolved to evade the immune system by increasing their surface expression of sialic acids in order to engage inhibitory Siglecs or to evade complement. In this review, we will s pecifically discuss the nuanced interactions between cancer cells and distinct Siglecs and their effect on immune cell regulation.
Sialic acids represent a structurally diverse family of nine-carbon sugars consisting of a pyranose ring bound to a carboxylic group and a three-carbon exocyclic side chain ( Figure 1 ). The carboxylic carbon is numbered C-1 while the ring includes C-2 through C-6, and the side chain includes C-7 to C-9. These bulky, electronegatively charged monosaccharides are derived from a neuraminic acid (Neu) backbone that can be N-acetylated at C-5 in the cytosol to form N-acetyl neuraminic acid (Neu5Ac), the metabolic precursor to sialic acid.
Biosynthesized Neu5Ac or sialic acid that has been recycled from the lysosome must first enter the nucleus where it is converted to cytidine monosphophate-sialic acid (CMP-Sia) by a nuclear enzyme, CMP-Sia synthetase. After returning to the cytosol, cytidine monophospho- Thus, the covalent linkages formed between the C-2 hydroxyl group of a sialic acid and the C-3 or C-6 positions of the preterminal galactose or N-acetylgalactosamine, are referred to as an α2-3 or α2-6 linkage respectively. If a second sialic acid is added to the glycan chain, the C-2 hydroxyl group of the terminal sialic acid is linked to the C-8 hydroxyl group of the preterminal sialic acid in an α2-8 linkage. 4 In addition to either an N-acetyl or N-glycolyl group at C-5, sialic acids are diverse in regards to modifications to their hydroxyl groups at carbon posi- Siglec-7 (p75/AIRM1) and Siglec-9 are members of the CD33-related Siglec family. The amino acid sequence of Siglec-9 is about 80% identical to the Siglec-7 sequence suggesting a gene duplication event during the evolution of these two Siglecs; they are localized on chromosome 19 with other CD33-related Siglecs.
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However, they exhibit distinct expression profiles among immune cell populations. 
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The extracellular portions of Siglec-7 and Siglec-9 contain three Ig-like domains while the cytoplasmic tail has one tyrosine residue within an ITIM and another tyrosine residue in a motif that is similar to one found in the SH2-domain containing SLAM-associated protein (SAP) binding site on the signaling lymphocyte activating molecule (SLAM), an immunomodulatory receptor. [12] [13] [14] 16 Thus, the membrane-proximal ITIM provides Siglec-7 and -9 expressing cells with the capacity for inhibitory signaling. 21 In fact, one group discovered Siglec-7 while investigating the inhibition of NK cell cytotoxicity in an in vitro cell killing assay. 13 However, after tyrosine phosphorylation of the ITIM, Siglec-7 recruits the SH2 domain-containing SHP-1 and SHP-2 tyrosine phophatases less efficiently than Siglec-9; this is because of a structurally different ITIM sequence. 22, 23 Cross-linking of Siglec-9 in neutrophils in an inflammatory environment has been shown to induce both apoptotic and caspase -independent cell death of the autologous cells secondary to the generation of reactive oxygen species (ROS). 24 In immunoprecipitation analyses, binding of DAP proteins to Siglec-7 is not detected perhaps due to the lack of basic amino acids in its transmembrane domain; these residues are typically present in other Siglecs that recruit adaptors of the DAP family.
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Aside from being an inhibitory receptor, Siglec-9 also possesses endocytic capabilities.
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Both Siglec-7 and Siglec-9 recognize α2,3-and α2,6-linked sialic acids in humans. [14] [15] [16] Siglec-7 preferentially binds to α2-6-linked sialic acids, but the underlying glycan structure of the ligand may also affect recognition. 12 Unlike Siglec-9, Siglec-7 has a preference for α2, has a weak affinity for murine Siglec-E. 34 These tumor proteins were shown to inhibit neutrophil-mediated tumor killing in co-culture assays measuring extracellular ROS formation while the addition of a blocking antibody induces higher cytotoxicity of target cells. Alternatively,
LGALS3BP downregulation can increase tumor cell apoptosis due to loss of Siglec-9 regulation on neutrophil activity. 
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Although Siglec-7 has been previously characterized as an inhibitory receptor, there is evidence to suggest that it has activating qualities solely in human monocytes. After exposing PBMC to a crosslinking monoclonal antibody directed against Siglec-7, the monocyte population was specifically activated and intracellularly expressed proinflammatory cytokines and chemokines while the blocking of Siglec-7 on these cells led to a decrease in the inflammatory response.
The activation of the monocyte population following Siglec-7 engagement may be due to the activation of ERK, a MAP kinase involved in the regulation of pro-inflammatory gene transcription. 41 These experiments suggest that Siglec-7 on monocytes may promote inflammation in addition to potentially inhibiting monocyte activation. In experiments where dead tumor cells were subcutaneously injected into mice, these cells traveled through the lymphatics to the draining lymph node where they could be phagocytosed by CD169 + macrophages utilizing a mechanism that is partly dependent on phophatidylserine recognition on the surface of the apoptotic cells. 
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. 102 Paradoxically, however, the tyrosine kinase Syk and phospholipase C-γ1 (Plcg1) can also dock onto phosphorylated tyrosine residues to form a complex with CD22 suggesting a counterbalance to the SHP-1 mediated signaling might exist. 97 In addition, the srcrelated non-receptor tyrosine kinase Lyn is required for the tyrosine phosphorylation of CD22 and SHP-1 recruitment and suppression of BCR signaling.
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The N-terminus of CD22 specifically interacts with N-linked oligosaccharide structures that terminate in accessible α2-6 linked sialic acids. Upon binding to CD52, Siglec-10 inhibited the phosphorylation of Lck and Zap70 tyrosine residues that are normally required for appropriate TCR signaling. 131 Siglecs-7 and/or -9 are also expressed on about 2%-18% of CD4 + and CD8 + T cells in the peripheral blood. 15, 16, 23 When
Jurkat cells are transfected with Siglec-7 and Siglec-9 and subjected to pervanadate treatment or TCR engagement, these ITIM-harboring inhibitory receptors co-localized with the T cell receptor. Siglec-7 and Siglec-9 both contributed to the recruitment of SHP-1, which mediates the dephosphorylation of the tyrosine phosphorylated CD3 complex and zeta ITAM tyrosines and results in reduced NFAT-mediated transcriptional activation.
23
A subset of T cells in the periphery express the GD3 ganglioside and anti-GD3 monoclonal antibodies have the ability to cause the proliferation of these cells as well as expansion of the GD3 + T cell population. 132 Purified CD169 protein is capable of binding to TK-1 lymphoma T cells in a sialic acid-dependent manner. Specifically, one of the glycan ligands for CD169 in this context is CD43, a sialomucin on T cells, and this may facilitate T cell-macrophage interactions.
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Additionally, it has been demonstrated that sialoadhesin/CD169 (described above), which is expressed on macrophages in inflamed organs in autoimmune mice, negatively regulated the expansion of Tregs as inferred from studies in sialoadhesin-deficient mice. 
